VIRUS News & Analysis

We take a closer look at the potential impact of remdesivir's nearly certain approval on our valuation model for Gilead.

Morningstar healthcare strategist Karen Andersen has increased her fair value estimate for the wide moat pharmaceutical company following positive...

Morningstar behavioural economist Sarah Newcomb reveals how she learned to stop worrying and love the ride.